Principal Investigators Roger Kamm , Ioannis Yannas , Xuanhe Zhao
In response to new business models, accelerated timelines, and unforeseen market dynamics, healthcare companies are seeking to innovate rapidly and effectively to meet new challenges. A key criterion for success is the adoption of cutting-edge tools that derisk and accelerate the drug development process. Investment in these tools pays dividends across a company's pipeline.
Principal Investigator Kevin Esvelt
Principal Investigator Lawrence Susskind
Principal Investigator Shiladitya Sengupta
C Cem Tasan
Principal Investigator M Toksöz